MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Dick, G. M.
Right arrow Articles by Sanders, K. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Dick, G. M.
Right arrow Articles by Sanders, K. M.

Vol. 61, Issue 5, 1105-1113, May 2002

Ethylbromide Tamoxifen, a Membrane-Impermeant Antiestrogen, Activates Smooth Muscle Calcium-Activated Large-Conductance Potassium Channels from the Extracellular Side

Gregory M. Dick, A. Christy Hunter, and Kenton M. Sanders

Department of Physiology and Cell Biology, University of Nevada School of Medicine, Reno, Nevada (G.M.D., K.M.S.), and School of Pharmacy and Biomolecular Sciences, University of Brighton, United Kingdom (A.C.H.)

Smooth-muscle calcium-activated large-conductance potassium channels (BK channels) are activated by tamoxifen and 17-beta -estradiol. This increase in NPo, the number of channels, N, multiplied by open probability, depends on the presence of the regulatory beta 1-subunit. Furthermore, a previous study indicated that 17-beta -estradiol might bind an extracellular site on the beta 1-subunit. Because tamoxifen and 17-beta -estradiol may share a common binding site, we hypothesized that tamoxifen activates BK channels through a site on the extracellular surface of the membrane. A membrane-impermeant analog of tamoxifen, ethylbromide tamoxifen, was synthesized and used to test this hypothesis in whole-cell, outside-out, cell-attached, and inside-out patches from canine colonic smooth muscle cells. Ethylbromide tamoxifen is positively charged and is therefore membrane-impermeant. In whole-cell experiments, ethylbromide tamoxifen increased K+ current at potentials positive to +40 mV, which has previously been attributed to BK channels. Unlike tamoxifen, ethylbromide tamoxifen did not inhibit delayed rectifier current. In outside-out patches, ethylbromide tamoxifen increased BK channel NPo with an EC50 value of 1 µM. Ethylbromide tamoxifen did not increase BK channel NPo in cell-attached or inside-out patches; however, subsequent addition of equimolar tamoxifen did. Both drugs diminished BK channel unitary conductance to a degree that paralleled the effect on NPo, suggesting an additional interaction with the pore-forming alpha -subunit. An interaction of tamoxifen with the pore was supported by a right shift in the concentration-response curve for tetraethylammonium; similar results were evident with iberiotoxin and charybdotoxin block. Our data suggest that ethylbromide tamoxifen does not easily traverse the plasma membrane and that tamoxifen binding responsible for activation of BK channels is at an extracellular site. The tamoxifen binding site may be within the extracellular loop of the BK channel beta 1-subunit or, alternatively, on an as-yet-unidentified mediator that has an extracellular binding site.


Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Mol. Pharmacol.Home page
T. S. Ha, H.-H. Lim, G. E. Lee, Y.-C. Kim, and C.-S. Park
Electrophysiological Characterization of Benzofuroindole-Induced Potentiation of Large-Conductance Ca2+-Activated K+ Channels
Mol. Pharmacol., March 1, 2006; 69(3): 1007 - 1014.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
G. J. Perez
Dual Effect of Tamoxifen on Arterial KCa Channels Does Not Depend on the Presence of the {beta}1 Subunit
J. Biol. Chem., June 10, 2005; 280(23): 21739 - 21747.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics